Hypnogen (Zolpidem Tartrate)

Zolpidem binds selectively to the benzodiazepine site of the GABAA receptor, enhancing the inhibitory action of the neurotransmitter GABA. This increased chloride influx hyperpolarises neurons, reducing central nervous system activity and promoting the onset and maintenance of sleep.

The appropriate dose of Hypnogen is determined by the prescribing clinician based on individual patient factors, regulatory guidelines, and local labeling. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for zolpidem in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a healthcare professional.

To order Hypnogen, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with benzodiazepine hypnotics, zolpidem has a shorter half‑life and a more selective binding profile, which generally results in fewer next‑day residual effects. However, it shares similar cautions regarding dependence, complex sleep behaviours, and interactions with other CNS depressants.

Hypnogen should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure they are out of reach of children.

Hypnogen is taken orally, usually shortly before bedtime. Patients should swallow the tablet whole with a glass of water and avoid consuming alcohol or other sedatives after taking the medication.

Serious risks include complex sleep behaviours such as sleep‑walking or sleep‑driving, severe allergic reactions, and worsening depression or emergence of suicidal thoughts. Any unusual or concerning symptoms should be reported to a healthcare provider immediately.

Hypnogen is contraindicated in patients with known hypersensitivity to zolpidem or any excipients, those with severe hepatic impairment, and individuals who have exhibited complex sleep behaviours with prior hypnotic use. It should also be avoided in patients taking prohibited CNS depressants without medical supervision.